All In Biotech

Drug Trial Radar · NCT00406419

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment

Last checked: Nov 20, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,015 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,015

Actual

Start

Dec 27, 2006

Primary completion

Oct 6, 2009

Study completion Apr 22, 2015

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Roche Pharma AG
First posted
Dec 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.

Conditions

  • Rheumatoid Arthritis

Interventions

  • MethotrexateDrug

    Methotrexate tablet was administered orally at a dose 7.5-25 mg

  • ocrelizumabDrug

    Ocrelizumab was administered via IV infusion at a dose specified in arm description

  • PlaceboDrug

    Matching placebo to ocrelizumab was administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24Time frame: Week 24
  2. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48Time frame: Week 48
  3. Percentage of Participants With Adverse Events (AEs)Time frame: From baseline up to 8.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Trial Information Support Line

    South San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.